|

Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT

RECRUITINGN/ASponsored by Massachusetts General Hospital
Actively Recruiting
PhaseN/A
SponsorMassachusetts General Hospital
Started2025-05-20
Est. completion2027-07-01
Eligibility
Age50 Years – 77 Years
Healthy vol.Accepted
Locations1 site

Summary

The goal of this clinical trial is to evaluate whether an AI tool that alerts providers to patients at high 6-year risk of lung cancer based on their chest x-ray images will improve lung cancer screening CT participation. The main question it aims to answer is: Does the AI tool improve lung cancer screening CT participation at 6 months after the baseline outpatient visit The intervention is an alert to the provider to discuss lung cancer screening CT eligibility, for patients considered at high risk of lung cancer based on CXR-LC AI tool. If there is a comparison group: Researchers will compare intervention and non-intervention arms to determine if lung cancer screen CT participation increases.

Eligibility

Age: 50 Years – 77 YearsHealthy volunteers accepted
Major Inclusion Criteria:

* Scheduled outpatient appointment with participating provider.
* 50- to 77-year-old who currently or formerly smoked, to include persons potentially eligible for lung screening based on Medicare guidelines.
* Recent (within 2 years) PA chest radiograph.

Exclusion Criteria:

• History or signs/symptoms of lung cancer. Recent (within 2 years) chest CT. Clinical indication for chest CT beyond lung cancer screening.

Conditions5

CancerDeep LearningEarly Cancer DetectionHealth ScreeningLung Cancer

Locations1 site

Massachusetts General Hospital
Boston, Massachusetts, 02114
Michael T Lu, MD, MPH617-724-9729mlu@mgh.harvard.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.